LONDON (Alliance News) - ANGLE PLC said Tuesday that it had seen a positive evaluation of its Parsortix system by the University of Manchester's Clinical and Experimental Pharmacology group.
Parsortix is used to capture circulating tumour cells from cancer patient blood for mutational analysis, using a simple blood test to capture the cancer cells for analysis.
The group, which is part of Cancer Research UK Manchester Institute, has evaluated the system. The group was impressed by the performance of the system for a variety of uses, and said it is now planning to use the it in future clinical studies, said ANGLE.
Amongst its key findings, it concluded that the system has potential advantages including its ability to capture circulating tumour cells that have weak cell market expression. It also noted that it does not require red cell lysis, is compatible with blood preservation collection tubes, and allows plasma collection from the same sample.
The group plans to use the system for clinical research work in colorectal and pancreatic cancer. A pilot study is now under way to evaluation the feasibility and potential clinical utility of routine use of the system to provide circulating tumour cells information for patients during treatment.
"It is of great importance to us that the CEP group believes in the potential of our Parsortix system to enable personalised cancer care," said Chief Executive Andrew Newland in a statement. "Their extensive work provides us with a platform to secure clinical studies with key opinion leaders, which is the key next step towards widespread adoption of the Parsortix system in the treatment of cancer."
Shares in ANGLE were trading down 1.0% at 74.25 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Angle (AGL)